Table 1
Components | ATX-L1 (study L1), DSPC, cholesterol and DMG-PEG2000
sales@dcchemicals.com
ATX L1
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Table 1
Molar ratio | Not specified in the supplied supporting information
Table 1
N/P; lipid:RNA mass ratio | Not specified in the supplied supporting information
Table 1
RNA aqueous phase | Citrate buffer, pH 3.5
Table 1
Lipid ethanol phase:aqueous phase | 1:3 (v/v)
Table 1
Post-mixing treatment | Threefold dilution with Tris buffer, pH 7.4; tangential-flow filtration with 10 diavolumes of Tris buffer; concentration adjustment with 100 kDa MWCO centrifugal filters; final 0.2 µm PES filtration
Table 2
Endpoint: Diameter | L1 result: 60 nm
Table 2
Endpoint: PDI | L1 result: 0.16
Table 2
Endpoint: Encapsulation | L1 result: 99.1%
Table 2
Endpoint: FVII knockdown at 0.03 mg/kg | L1 result: 84%
Table 2
Endpoint: FVII knockdown at 0.01 mg/kg | L1 result: 63%
Table 2
Endpoint: FVII ED50 | L1 result: <0.01 mg/kg
Table 3
Lipid: L1 | Diameter / PDI: 60 nm / 0.16 | Encapsulation: 99.1% | FVII KD, 0.03 / 0.01 mg/kg: 84% / 63% | ED50, mg/kg: <0.01
Table 3
Lipid: L2 | Diameter / PDI: 67.46 nm / 0.142 | Encapsulation: 99.4% | FVII KD, 0.03 / 0.01 mg/kg: 96% / 83% | ED50, mg/kg: <0.01
Table 3
Lipid: L5 | Diameter / PDI: 70.21 nm / 0.104 | Encapsulation: 97.4% | FVII KD, 0.03 / 0.01 mg/kg: 81% / 43% | ED50, mg/kg: 0.014
Table 4
L1 dose: 1 mg/kg | 2 h: RC | 6 h: N | 24 h: N | 48 h: N
Table 4
L1 dose: 3 mg/kg | 2 h: RC | 6 h: N | 24 h: N | 48 h: N
Table 4
L1 dose: 5 mg/kg | 2 h: RC3, HP3 | 6 h: RC2, HP | 24 h: RC | 48 h: RC